Schonfeld Strategic Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-107,251
| Closed | -$5.26M | – | 2399 |
|
|
2025
Q4 | $5.26M | Sell |
107,251
-242,667
| -69% | -$11.3M | 0.02% | 526 |
|
|
2025
Q3 | $15.1M | Sell |
349,918
-243,130
| -41% | -$9.5M | 0.09% | 244 |
|
|
2025
Q2 | $22.8M | Sell |
593,048
-213,459
| -26% | -$8.16M | 0.15% | 137 |
|
|
2025
Q1 | $31.2M | Sell |
806,507
-1,430,527
| -64% | -$52.4M | 0.19% | 79 |
|
|
2024
Q4 | $75.7M | Buy |
2,237,034
+907,068
| +68% | +$32.7M | 0.44% | 21 |
|
|
2024
Q3 | $54.4M | Buy |
1,329,966
+1,248,923
| +1,541% | +$51.1M | 0.36% | 27 |
|
|
2024
Q2 | $3.12M | Sell |
81,043
-529,295
| -87% | -$22.3M | 0.02% | 718 |
|
|
2024
Q1 | $26.2M | Sell |
610,338
-71,562
| -10% | -$2.95M | 0.17% | 113 |
|
|
2023
Q4 | $25.3M | Buy |
681,900
+173,298
| +34% | +$6.22M | 0.17% | 118 |
|
|
2023
Q3 | $18.4M | Sell |
508,602
-152,797
| -23% | -$5.42M | 0.14% | 199 |
|
|
2023
Q2 | $23.6M | Buy |
661,399
+328,060
| +98% | +$11.8M | 0.2% | 150 |
|
|
2023
Q1 | $11.9M | Buy |
333,339
+84,207
| +34% | +$2.95M | 0.11% | 244 |
|
|
2022
Q4 | $8.75M | Sell |
249,132
-65,768
| -21% | -$2.19M | 0.07% | 333 |
|
|
2022
Q3 | $9.27M | Buy |
+314,900
| New | +$11.9M | 0.08% | 333 |
|
|
2022
Q2 | – | Sell |
-136,116
| Closed | -$7.41M | – | 2715 |
|
|
2022
Q1 | $7.41M | Sell |
136,116
-70,643
| -34% | -$3.84M | 0.07% | 332 |
|
|
2021
Q4 | $11.4M | Buy |
206,759
+88,563
| +75% | +$4.61M | 0.1% | 262 |
|
|
2021
Q3 | $5.64M | Buy |
+118,196
| New | +$5.94M | 0.06% | 401 |
|
|
2020
Q3 | – | Sell |
-42,195
| Closed | -$2.15M | – | 1483 |
|
|
2020
Q2 | $2.15M | Buy |
42,195
+20,501
| +95% | +$1.05M | 0.06% | 387 |
|
|
2020
Q1 | $1.03M | Buy |
+21,694
| New | +$1.16M | 0.06% | 358 |
|
|
2019
Q2 | – | Sell |
-5,520
| Closed | -$288K | – | 1089 |
|
|
2019
Q1 | $288K | Buy |
+5,520
| New | +$276K | 0.01% | 845 |
|
|
2018
Q4 | – | Sell |
-9,760
| Closed | -$490K | – | 1132 |
|
|
2018
Q3 | $490K | Buy |
+9,760
| New | +$496K | 0.02% | 581 |
|
|
2018
Q1 | – | Sell |
-36,462
| Closed | -$1.62M | – | 855 |
|
|
2017
Q4 | $1.62M | Buy |
+36,462
| New | +$1.68M | 0.13% | 214 |
|
|
2017
Q3 | – | Sell |
-6,342
| Closed | -$342K | – | 669 |
|
|
2017
Q2 | $342K | Sell |
6,342
-5,008
| -44% | -$267K | 0.04% | 448 |
|
|
2017
Q1 | $599K | Buy |
+11,350
| New | +$576K | 0.06% | 339 |
|
|
2016
Q4 | – | Sell |
-5,454
| Closed | -$294K | – | 590 |
|
|
2016
Q3 | $294K | Buy |
5,454
+474
| +10% | +$26K | 0.05% | 320 |
|
|
2016
Q2 | $270K | Buy |
+4,980
| New | +$262K | 0.06% | 331 |
|
Other funds holding GSK
JEST
Schonfeld Strategic Advisors's GSK Position: Q1 2026 in Review
Schonfeld Strategic Advisors sold out of GSK (GSK) in Q1 2026, closing a stake of 107,251 shares — an estimated $5.26M sold.
Schonfeld Strategic Advisors first reported a position in GSK in Q2 2016 and held it in 26 quarters. The position peaked at $75.7M in Q4 2024. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Schonfeld Strategic Advisors reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 107,251 GSK shares in Q1 2026, an estimated $5.26M.
- Schonfeld Strategic Advisors first reported a position in GSK in Q2 2016 and held it in 26 quarters.
- Schonfeld Strategic Advisors's GSK position peaked at $75.7M in Q4 2024.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.